Wether VNS in Early Stage (3 Months) is Safe and More Beneficial for Post-stroke Motor Rehabilitation

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age30-75
SponsorQilu Hospital of Shandong University

About this trial

Upper-extremity impairment after stroke remains a major therapeutic challenge and a target of neuromodulation treatment efforts. In previous study, Vagus nerve stimulation was constricted to patients 9 months after stroke. In this randomized phase I trial, we would apply vagus nerve stimulation in an early stage (\<6 month) and observe its theraputic effect on motor function after ischaemic Stroke.We hypothesized that the early stimulation could be safe and more beneficial compared to stimulation in late stage.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Eligible individuals suffered a first-time, unilateral, ischemic stroke in the middle cerebral artery territory that spared the diencephalon and basal ganglia 3-36 months before surgery.

Individuals with persistent moderate-to-severe upper-extremity hemiparesis as defined by an FM-UE score of ≤42

Sufficient upper-extremity motor ability to engage in rehabilitation (that is, a score of ≥1 on the FM-UE elbow flexion, elbow extension or finger mass flexion or extension).

Disqualifiers

Excessive spasticity or contracture of the upper-extremity muscles (that is, Modified Ashworth Scale = 4) . Severe cognitive impairment (Mini Mental State Examination < 24)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Vagus Nerve Stimulation in early stage

    Device

    Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region.

  • Vagus Nerve Stimulation in late stage

    Device

    Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region

Treatment groups

100 Participants
are divided into 3 treatment groups
Group A: VNS activated in late stageExperimental treatment 1 intervention
Group B: VNS activated in early stageActive comparator 1 intervention
Group C: VNS not activated in early stageExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

FM-UE scores between early and late VNS

The outcomes includes each participant's Fugl-Meyer assessment scale (FM-UE) scores for each monthly visit. FM-UE scores range from 0 to 100 and the higher scores indicated better outcome of movement.

Time frame
12 months after device implantation

Secondary outcomes

1

Arm Motor Ability Test (AMAT) between early and late VNS

The outcomes includes each participant's the Arm Motor Ability Test (AMAT) for each monthly visit. AMAT scores range from 0 to 57 and the higher scores indicated better outcome of movement.

Time frame
12 months after device implantation
2

the Nine-Hole Peg Test between early and late VNS

The outcomes includes each participant's the Nine-Hole Peg Test for each monthly visit.

Time frame
12 months after device implantation
3

the Bilateral Box and Block Test between early and late VNS

The outcomes includes each participant's the Bilateral Box and Block Test for each monthly visit.

Time frame
12 months after device implantation
4

Short Form Health Survey (SF-12) between early and late VNS

The outcomes includes each participant's score of Short Form Health Survey (SF-12) for each monthly visit. SF-12 scores range from 0 to 60 and the higher scores indicated better outcome of movement.

Time frame
12 months after device implantation

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.